COMMUNIQUÉS West-GlobeNewswire

Cellectis présentera deux posters sur un nouveau procédé d’édition par TALEN® pour la correction et l’insertion de gènes dans les cellules souches et progénitrices hématopoïétiques (HSPCs) à l’ASGCT
08/04/2024
NEW YORK, 08 avr. 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome TALEN ® pour développer [...]
Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
08/04/2024
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving [...]
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
08/04/2024
SAN FRANCISCO, April 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
08/04/2024
Novel camptothecin-peptide conjugates are well tolerated and associated with significant tumor regression in colorectal cancer and triple-negative breast cancer xenograft models SORT1 gene silencing results in drastic [...]
Theratechnologies présente des données précliniques au congrès 2024 de l’AACR qui met en évidence la polyvalence et la flexibilité de la plateforme technologique d’oncologie SORT1+(MC)
08/04/2024
Les nouveaux conjugués camptothécine-peptide sont bien tolérés et associés à une régression tumorale marquée dans les modèles de xénogreffe de cancer colorectal et de cancer du sein triple négatif L’inactivation du gène [...]
iCAD’s ProFound AI Suite Uncovers Hidden Heart Disease Risk According to New Data Presented at American College of Cardiology Meeting
08/04/2024
Study confirms iCAD’s Breast Arterial Calcification AI Algorithm successfully detects calcification of breast vessels, an indicator of cardiovascular disease, from mammograms NASHUA, N.H., April 08, 2024 (GLOBE NEWSWIRE [...]
IBEX Completes Sale of the Company
08/04/2024
MONTRÉAL, April 08, 2024 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) announces that it has completed the sale of the company by amalgamating with 15720273 Canada Inc., a newly [...]
CoreRx, Inc. Completes Acquisition of Societal CDMO, Inc.
08/04/2024
CLEARWATER, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- CoreRx, Inc. (“CoreRx”) today announced that it has completed its acquisition of Societal CDMO, Inc. (“Societal CDMO”) (Nasdaq: SCTL), a contract development and [...]
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting
08/04/2024
PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and [...]
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights
08/04/2024
BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells [...]
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
08/04/2024
RAS-mutated mCRC – In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor’s ability to adapt to hypoxia resulting in a significant decrease in both tumor vascularization and growth [...]
Shockwave Reducer Demonstrates Consistent, Positive Results in ‘Real-World’ Study
08/04/2024
Six-Month Results from REDUCER-I Trial Add to Positive Evidence of the Coronary Sinus Reducer to Treat Refractory Angina SANTA CLARA, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a [...]
Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
08/04/2024
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical safety and tolerability profile observed with no dose limiting toxicities [...]
Longeveron Announces Pricing of $5.25 Million Public Offering
08/04/2024
MIAMI, April 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related [...]
Smart for Life Releases Corporate Video on Definitive Agreement to Acquire Purely Optimal Nutrition
08/04/2024
CEO of Smart for Life Discusses Profitable Acquisition Expected to Contribute More than $8 Million of Annualized Revenue and Over $1 Million of Adjusted EBITDA MIAMI, April 08, 2024 (GLOBE NEWSWIRE) -- Smart for Life, [...]
Transparency Notifications from Shareholders
08/04/2024
PRESS RELEASE REGULATED INFORMATION 8 April 2024, 06:30 pm CEST Ghent, Belgium – 8 April 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), a pioneer in the treatment of fluid [...]
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
08/04/2024
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length [...]
Merus présente des données précliniques démontrant l’efficacité de Zeno dans le traitement des modèles de cancer avec une forte expression du gène NRG1 lors de la réunion annuelle 2024 de l’AACR
08/04/2024
UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 08 avr. 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS) (« Merus », la « Société », « nous » ou « notre »)/« nos », une société spécialisée dans l’oncologie au stade [...]
Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the Platform
08/04/2024
FOSTER CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing a new class of cancer therapies identified [...]

Pages